Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.

doi:10.1158/1078-0432.CCR-21-0935

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2021

Hunter Anthony M, Newman Hannah, Dezern Amy E, Steensma David P, Niyongere Sandrine, Roboz Gail J, Mo Qianxing, Chan Onyee, Gerds Aaron, Sallman David A, Dominguez-Viqueira William, Letson Christopher, Balasis Maria E, Ball Markus, Kruer Traci, Zhang Hailing, Lancet Jeffrey E, List Alan F, Sekeres Mikkael A, Komrokji Rami S, Padron Eric

Abstract excerpt

PURPOSE: Chronic myelomonocytic leukemia (CMML) is a rare leukemia characterized by peripheral monocytosis with no disease-modifying therapies. CMML cells are uniquely hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) and robustly engraft in immunocompromised mice that secrete human cytokines. To leverage these unique biological features, we conducted an integrated human and murine study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cytokines

Share to Drug Evaluation, Preclinical

Share to Leukemia, Myelomonocytic, Chronic

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 34253584
DOI: 10.1158/1078-0432.CCR-21-0935
PMCID: PMC8595542

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.PMID 34253584Read ↗

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).Semantic proximity Read ↗

Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms.Semantic proximity Read ↗

Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.Semantic proximity Read ↗

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsSemantic proximity Read ↗

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.Semantic proximity Read ↗

Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.Semantic proximity Read ↗

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.